EODData

MEMBERSHIP REGISTER LOG IN

FRA, 6GJ: Glaukos Corporation

07 Nov 2025
LAST:

70.00

CHANGE:
 2.00		OPEN:
70.00		HIGH:
70.00		ASK:
0.00		VOLUME:
41
CHG(%):
2.78		PREV:
72.00		LOW:
70.00		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
07 Nov 2570.0070.0070.0070.0041
06 Nov 2572.0072.0072.0072.0041
05 Nov 2573.5073.5073.5073.5041
04 Nov 2574.5074.5074.5074.5041
03 Nov 2575.5075.5075.5075.5041
31 Oct 2575.5075.5075.5075.5041
30 Oct 2579.0079.0078.0078.0041
29 Oct 2566.0066.0066.0066.0041
28 Oct 2564.0064.0064.0064.0041
27 Oct 2563.5063.5063.5063.5041

COMPANY PROFILE

Name:Glaukos Corporation
About:Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. The company offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. It also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension; iAccess, a precision blade; and iPRIME, a viscoelastic delivery system. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
Sector:Healthcare
Address:One Glaukos Way, Aliso Viejo, CA, United States, 92656
Website:https://www.glaukos.com
ISIN:US3773221029
LEI:5299004JA1LHE21M6T14

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-26.90 
Forward P/E:-52.10 
PEG Ratio:0.40 
Price to Sales:9.18 
Price to Book:5.56 
Profit Margin:-0.19 
Operating Margin:-0.12 
Return on Assets:-0.06 
Return on Equity:-0.12 
Revenue:407.76M 
Shares:57.35M 
Market Cap:4.015B 

TECHNICAL INDICATORS

MA5:73.104.4%
MA10:71.251.8%
MA20:70.280.4%
MA50:72.303.3%
MA100:76.759.6%
MA200:87.7125.3%
STO9:40.00
STO14:41.94
RSI14:44.12
WPR14:-55.17
MTM14:2.50
ROC14:0.04 
ATR:2.50 
Week High:75.507.9%
Week Low:70.000.0%
Month High:79.0012.9%
Month Low:63.5025.3%
Year High:153.01118.6%
Year Low:63.5010.2%
Volatility:15.39